CATX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CA

Mkt Cap

$248.3M

Volume

1.58M

Next Earnings

November 9th

Loading chart

CA

CATXPerspective Therapeutics, Inc.

CATX

Pay with—

Available Balance0.00

CA

Mkt Cap

$255.7M

Volume

1.58M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?Profound Medical (PROF) surged 21.7% following strong preliminary Q3 2026 revenue guidance of $9.8-10 million, representing 85-89% year-over-year growth and 45-47% above analyst consensus. The company expects gross margins exceeding 70%, signaling improved commercial momentum. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock's momentum may not sustain without further positive estimate revisions.Zacks Investment Research · Oct 9, 2026

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in MelanomaPerspective Therapeutics announced it will present updated clinical data from all three of its radiopharmaceutical programs at the 2026 ASCO Annual Meeting. Key highlights include one new responder in the [212Pb]VMT01 melanoma monotherapy cohort (29% response rate), advancement of [212Pb]PSV359 to Cohort 3 with favorable safety profile, and continued deepening of responses in [212Pb]VMT-α-NET for neuroendocrine tumors. All programs demonstrated good tolerability with no dose-limiting toxicities reported.GlobeNewswire Inc. · May 21, 2026

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightThe pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.GlobeNewswire Inc. · Apr 20, 2026

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual MeetingPerspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a first-in-class 212Pb-radiopharmaceutical targeting SSTR2-positive neuroendocrine tumors. The trial showed a 43% objective response rate in Cohort 2 patients, with no dose-limiting toxicities or serious treatment-related complications. The company plans to submit clinical evidence for regulatory engagement in 2026.GlobeNewswire Inc. · Apr 20, 2026

Perspective Therapeutics to Participate in Upcoming Investor ConferencesPerspective Therapeutics, a radiopharmaceutical development company, announced that its senior leadership will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, and the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company is developing advanced cancer treatments using alpha-emitting isotope 212Pb with complementary imaging diagnostics, with programs in Phase 1/2a trials for neuroendocrine tumors, melanoma, and solid tumors.GlobeNewswire Inc. · Apr 2, 2026

New Treatment Modalities Are Reaching Cancers That Resisted Everything ElseSeveral biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.Benzinga · Feb 17, 2026

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial ResultsPerspective Therapeutics, a radiopharmaceutical development company, announced it will report its full year 2025 financial results and provide a business update on March 16, 2025. The company is developing advanced cancer treatments using alpha-emitting isotope 212Pb with theranostic imaging capabilities, with multiple programs in Phase 1/2a trials.GlobeNewswire Inc. · Feb 17, 2026

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers SymposiumPerspective Therapeutics will present updated data on its [212Pb]VMT-α-NET program at the ASCO Gastrointestinal Cancers Symposium in January 2026, highlighting promising safety and efficacy results for neuroendocrine tumor treatment.GlobeNewswire Inc. · Dec 4, 2025

Perspective Therapeutics to Participate in Upcoming December ConferencesRadiopharmaceutical company Perspective Therapeutics announced participation in upcoming healthcare conferences and highlighted its ongoing cancer treatment research using alpha-emitting isotope 212Pb technology.GlobeNewswire Inc. · Nov 20, 2025

Perspective Therapeutics to Participate in Upcoming November ConferencesRadiopharmaceutical company Perspective Therapeutics will participate in upcoming investor conferences, showcasing its advanced cancer treatment technology utilizing alpha-emitting isotope 212Pb for targeted radiation therapy.GlobeNewswire Inc. · Oct 31, 2025

to start trading

CA

CATXPerspective Therapeutics, Inc.

CATX

Pay with—

Available Balance0.00

Your PositionYou don't own any CATX yet.

Related Tickers

Earnings